Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

immunogenic cell death inducer CAN2109

A long-acting, bi-functional immunogenic cell death (ICD) inducer, with potential immunostimulating and antineoplastic activities. Upon intratumoral (IT) administration, ICD inducer CAN2109 may directly kill tumor cells through as of yet undisclosed mechanism of action (MoA). This releases tumor neoantigens, which may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the neoantigens, resulting in tumor cell lysis. CAN2109 retains in the tumor microenvironment (TME) for a long time with minimal release to the systemic circulation after IT administration.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ICD inducer CAN2109
Code name:CAN 2109
CAN-2109
CAN2109
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search